Background: Chemotherapy in combination with small-molecule epidermal growth factor receptor inhibitors has yielded inconsistent results. Based on preclinical models, we conducted a phase I trial of two schedules of lapatinib and vinorelbine.
introduction
The epidermal growth factor receptor (EGFR or HER1) and human epidermal growth factor receptor 2 (HER2) are members of a tyrosine kinase family of transmembrane receptors, which are mutated, overexpressed, or amplified in a number of human cancers [1] . Single-agent activity has been reported with the use of multiple agents targeting the EGFR pathway including trastuzumab, the monoclonal antibody to HER2 [2] ; lapatinib, a tyrosine kinase inhibitor (TKI) of EGRF and HER2 [3] ; erlotinib [4, 5] and gefitinib [6] , both EGFR TKIs; and cetuximab, the monoclonal antibody to EGFR [7] . Moreover, the combination of these targeted therapies with chemotherapy has been investigated in a variety of solid tumors. In early and advanced HER2-positive breast cancer, synergy between chemotherapy and HER2-directed therapy has significantly improved outcomes, including survival, compared with chemotherapy alone [8] [9] [10] [11] . Similarly, trastuzumab in addition to chemotherapy in HER2-positive gastroesophageal and gastric adenocarcinomas resulted in a survival advantage [12] . In advanced colorectal cancer, the addition of cetuximab to chemotherapy improved outcomes in patients whose tumors had wild-type K-ras [13, 14] .
In contrast, despite preclinical data supporting additive to synergistic effects when EGFR TKIs are combined with chemotherapy, four phase III trials comparing the combination of EGFR TKIs and platinum-based chemotherapy to chemotherapy alone in non-small-cell lung cancer (NSCLC) failed to show improvements in response rates or survival [15] [16] [17] [18] . Multiple explanations have been offered, including lack of patient selection, especially with the subsequent discovery of EGFR-activating mutations in NSCLC [19, 20] . Alternatively, an antagonistic interaction between EGFR TKIs and chemotherapy in cancers with wild-type EGFR may account for the lack of benefit of combination therapy in previous trials [21] . Preclinical models suggest that while EGFR TKIs are cytotoxic in NSCLC cell lines harboring EGFR-activating mutations, inducing apoptosis through caspase-related mechanisms, they are primarily cytostatic in EGFR wild-type cell lines [21, 22] . Evidence supporting sequence-specificity and schedule-dependent interactions of EGFR TKIs and chemotherapy suggest that intermittent EGFR dosing between chemotherapy cycles, to achieve pharmacodynamic separation, might prove efficacious [23] [24] [25] [26] . We previously investigated erlotinib in combination with docetaxel and pemetrexed and demonstrated feasibility and tolerability [27] .
To extend and test this hypothesis further, we chose to evaluate intermittent and continuous dosing of lapatinib in combination with vinorelbine. Lapatinib is a potent, oral smallmolecule TKI that targets EGFR and HER2. When combined with capecitabine, lapatinib improved time to progression compared with capecitabine alone in patients with advanced HER2-positive breast cancer that had progressed on trastuzumab [11] . The addition of lapatinib resulted in increased diarrhea, dyspepsia, and rash, but no increase in cardiac or hematologic toxic effects. Vinorelbine is primarily used to treat advanced NSCLC and breast cancer [28] [29] [30] [31] . As a single agent, it is well tolerated, with cytopenias and neuropathy being the most common toxic effects.
We conducted a multi-institutional phase I study of lapatinib and vinorelbine. The rationale was to optimize synergy of the combination by exploring intermittent and continuous dosing of EGFR inhibition with chemotherapy. The objectives of this phase I study were to evaluate the safety and efficacy and to define the maximum tolerated dose (MTD) of the two different schedules of this combination. Biological correlates, including tumor PTEN, EGFR, and pAKT expression, and PTEN and K-ras mutation analyses were carried out. patients and methods eligibility Eligible patients had cytologically or histologically confirmed advanced solid tumors and progressive disease after no more than two prior regimens for metastatic cancer. Patients were ‡18 years with a Zubrod performance status of zero to two, and an estimated survival ‡3 months. All prior systemic therapy was completed ‡4 weeks, and radiation therapy was completed ‡2 weeks, before the start of protocol therapy. Patients had adequate hematologic, renal, hepatic, and cardiac function indicated by an absolute neutrophil count (ANC) ‡ 1500/ ll, platelets ‡ 100 000, creatinine £ 1.5 mg/dl or creatinine clearance ‡ 40 ml/ min, bilirubin £ 1.5 mg/dl, aspartate aminotransferase SGOT £ 3 times the institutional limit of normal, and cardiac ejection fraction within the institutional limit of normal by echocardiogram or Multiple Gated Acquisition scan. Patients with a history of brain metastases were allowed if they had been treated, were asymptomatic, and were off of corticosteroids and anticonvulsants for >4 weeks. Patients were excluded if they had received prior lapatinib, vinorelbine, or other EGFR/HER1-targeted therapy. Prior trastuzumab was allowed. Patients were excluded if they were pregnant or breastfeeding, had preexisting neuropathy grade 2 or more, were HIV positive, or were unable to take oral medication. All patients had to adhere to requirements regarding concomitant use of medications classified as CYP34A inhibitors or inducers or gastric pH modifiers.
All patients were informed of the investigational nature of the study and provided voluntary written informed consent in accordance with institutional and federal guidelines. Each protocol was approved by the respective institutional review boards of all participating sites.
dose-limiting toxic effects
Toxic effects were graded according to the National Cancer Institute Common Terminology Criteria (NCI CTC, Version 3.0) available at http:// ctep.cancer.gov/protocolDevelopment/. A dose-limiting toxicity (DLT) occurring in the first cycle of treatment was defined as grade 4 thrombocytopenia, grade 3 thrombocytopenia with bleeding or transfusion, febrile neutropenia, or any grade 3 or more non-hematologic toxic effect felt to be clinically significant and related to protocol therapy, with the exception of inadequately treated nausea, vomiting, and diarrhea. The MTD was defined as the highest dose tested in which fewer than 33% of patients experienced a DLT, when at least six patients were treated at that dose and assessable for toxic effect. The MTD is one dose level below the lowest dose tested in which ‡33% of patients experienced a DLT. At least six patients were treated at the MTD.
treatment plan and dose modifications
This phase I study was designed to evaluate the tolerability and feasibility of two different schedules of lapatinib in combination with vinorelbine. Patients were accrued from four academic cancer centers in cohorts of three to alternating arms of continuous (arm A) or intermittent (arm B) lapatinib in combination with weekly vinorelbine on a 28-day cycle (Table 1) . Accrual on one arm began after accrual to the dose level on the alternate arm was completed. Accrual and dose escalation in this alternating fashion continued until the MTD was reached in each arm. This was not designed as a comparative study, but rather like two separate phase I trials, with each arm accruing sequentially.
Patients without evidence of progressive disease or unacceptable toxic effects were allowed to continue treatment indefinitely on the same dose and schedule assigned. After six cycles of vinorelbine, patients were allowed to receive lapatinib alone.
Supportive measures for grade 1-2 toxic effects due to lapatinib included antidiarrheals for diarrhea and topical antibiotics and antihistamines for rash. Lapatinib was held for grade 3 and 4 toxic effects, until recovery to grade 1 or less, and then restarted at one dose level lower (<250 mg, see Table 1 ). If the existing lapatinib dose level was 250 mg, no further reductions were allowed and patients were removed from study. If treatment was delayed >3 weeks due to toxic effects, patients were taken off study. The left ventricular ejection removed from study. Doses that were held were deleted and not administered at a later time. All dose reductions were permanent and if treatment was held >3 weeks due to toxic effects, the patient was removed from study.
response assessment
Baseline computed tomography (CT) scans were carried out within 4 weeks of protocol treatment. Disease was reassessed every 8 weeks and evaluation of response for measurable disease was based on RECIST criteria. For patients who received >10 cycles of protocol therapy, CT scan frequency was lengthened to every 12 weeks at the discretion of the treating physician. 
toxic effects
Grade 3 and 4 toxic effects are shown in Table 3 . There were no treatment-related deaths. The most common grade 3 and 4 toxic effects include leukopenia (42% and 45% in arms A and B, respectively) and neutropenia (42% and 78% in arms A and B, respectively). Grade 3 fatigue was reported in 9% of Arm A and 28% of arm B. Two patients on arm A and one patient on arm B experienced grade 3 diarrhea and one patient had grade 3 rash. There were no grade 3 or 4 cardiac toxic effects. Forty-two patients were assessable for DLT, 27 on arm A and 15 on arm B. Three patients on arm A experienced DLTs, including grade 3 infection, at dose level A3, and recurrent grade 3 diarrhea and febrile neutropenia, both at dose level A6. There were two DLTs on arm B, grade 3 bone pain at dose level B2, and grade 3 fatigue at dose level B3. All DLTs resolved. The arm A MTD was vinorelbine 20 mg/m 2 weekly and lapatinib 1500 mg daily. The arm B MTD was vinorelbine 25 mg/m 2 weekly and intermittent lapatinib 1500 mg.
clinical response
Patients assessable for response on arm A and arm B were 25 and 16 in number, defined as completing two cycles of therapy. There was 1 patient with a complete response (CR), 1 with a partial response (PR), and 11 with stable disease (SD) on arm A. There was one patient with a CR, two with PR, and eight with SD on arm B. Both patients with CRs had HER2-positive metastatic breast cancer that had progressed on prior trastuzumab. The patients with a PR had advanced breast cancer, prostate cancer, and papillary thyroid carcinoma.
correlative studies
Analysis of factors predicted to impact on the efficacy of lapatinib were analyzed in available archival tumor tissue specimens from enrolled and consented patients. Of patients 
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with evaluable clinical data, 23 had specimens sufficient for molecular analysis of at least one marker. A summary of patients and molecular results is provided in Table 4 . Markers assessed included EGFR, phospho-AKT, and PTEN expression by IHC and mutational analysis of K-ras and PTEN. Laboratory analysis was conducted blinded to patient outcomes. In this original articles Annals of Oncology limited study of heterogeneous tumor types, no correlations were observed between biomarker status and patient outcome, with the exception of PTEN expression. PTEN expression by IHC demonstrated a significant association with patient time to progression (TTP). As shown in Figure 1 , loss of PTEN tumor staining generally associated with a more rapid TTP. Figure 1 plots patient TTP against PTEN staining. When stratified at the median TTP for this cohort, patients who progressed more rapidly were significantly more likely to harbor a loss of PTEN expression (P = 0.03, twosided Fisher's exact test). Figure 2 is a Kaplan-Meier curve of TTP stratified by PTEN expression, revealing a significantly improved outcome in patients with normal PTEN tumor expression (P = 0.0027, log-rank test). Figure 3 shows representative examples of tumors from enrolled patients staining positively and negatively for PTEN.
discussion
To our knowledge, this is the first completed phase I study of the combination of vinorelbine and lapatinib. The purpose of this trial was to evaluate the safety and tolerability of two different schedules of EGFR inhibition based on the hypothesis that intermittent dosing of an EGFR inhibitor would enhance synergy with chemotherapy, compared with continuous dosing [23] . While this has been hypothesized in NSCLC, antagonism between cytotoxic chemotherapy and cytostatic targeted therapy was demonstrated in a phase III trial in early-stage breast cancer [32] . Albain et al. [32] reported significantly improved diseasefree survival when adjuvant tamoxifen was sequenced after chemotherapy, compared with concurrent dosing.
Both schedules of lapatinib and vinorelbine were well tolerated, with no unforeseen adverse events. The most common grade 3 and 4 toxic effects were leukopenia, neutropenia, and fatigue. The higher percentage of grade 3 and 4 neutropenia and fatigue on arm B may be due to a higher #48  #6  #5  #25  #37  #13  #22  #16  #21  #17  #3  #29  #34  #26  #50  #49  #32  #9  #12  #14  #44 
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MTD of weekly vinorelbine compared with arm A. The MTDs on both arms are similar to doses of single agent vinorelbine or lapatinib or their use in combination regimens. In a trial of firstline therapy for metastatic HER2-positive breast cancer, vinorelbine and trastuzumab resulted in similar rates of grade 3 and 4 neutropenia (56%) [33] . The combination of capecitabine and lapatinib resulted in higher rates of grade 3 and 4 diarrhea (13%) and rash (7%), than observed in the present study [11] .
In this unselected population, activity was seen on both treatment schedules. The two patients who achieved a CR had HER2-positive breast cancer. A phase II trial of vinorelbine and trastuzumab in HER2-positive advanced breast cancer reported response rates of 75%, including a CR rate of 8% [33] . Nearly half of the patients on that trial had not had prior therapy for metastatic disease and HER2 status was determined by IHC, allowing both 3+ (75%) and 2+ (25%) staining tumors. A higher response rate was seen in patients receiving first-line therapy and who had tumors that stained 3+ for HER2. Lapatinib is also active in this population and is approved in combination with capecitabine in advanced HER2-overexpressed or HER2-amplified breast cancer that has progressed on anthracyclines, taxanes, and trastuzumab [11] . The role of EGFR as a clinical target in breast cancer is unclear. In a phase II trial of lapatinib monotherapy in advanced HER2-positive and/or EGFR-positive breast cancer, 50% of patients with HER2-positive breast cancer had a response. In contrast, only 1 out of 15 patients with HER2-negative and EGFR-positive breast tumors responded to lapatinib [34] . How best to determine EGFR status and its clinical utility in breast cancer remains uncertain. Based on the arm A MTD of this phase I trial, a single-arm phase II study of continuous lapatinib and weekly vinorelbine in patients with HER2-positive breast cancer is under way.
Correlative studies of biomarkers considered to have a potential impact on lapatinib activity were explored in a subset of patients. In a phase I study with heterogeneous tumor types, dosing, and schedules, such studies are by definition exploratory and hypothesis generating. Mutational analysis of K-ras and PTEN revealed no overt correlations with outcomes. The functional consequences of the observed base substitutions in PTEN are not known. Expression of EGFR and positivity of pAKT were noted in only a few specimens (Table  4) , with the additional caveat that lack of pAKT may result from signal degradation before fixation.
In contrast, loss of PTEN expression by IHC significantly associated with shorter TTP (Figure 1) . A growing body of evidence suggests that PTEN abnormalities, particularly epigenetic silencing, confer resistance to trastuzumab in HER2-positive breast cancer [35] . These observations are consistent with the expectation that loss of PTEN function results in dysregulated hyperactivity of PI3K and subsequent downstream signaling, to varying extents decoupling PI3K-AKT signaling from upstream tyrosine kinase receptors. Although a similar resistance effect from PTEN loss would be anticipated for lapatinib, in vitro studies have not always recapitulated the results found for trastuzumab [36, 37] , Divergent results from others demonstrated that loss of PTEN confers lapatinib resistance [38] .
In the context of this heterogeneous phase I trial, it is impossible to distinguish prognostic from predictive effects. Thus, the association between PTEN loss and tumor progression may result from a more aggressive phenotype conferred by PTEN loss or alternatively, reflect tumor types more likely to harbor a silenced PTEN. Of the 13 cases of breast cancer, patients with tumor PTEN loss averaged a TTP of 69 days (n = 7) versus 369 days (n = 6) among those with normal PTEN, a significant divergence in outcome (P = 0.027, twotailed t-test), albeit poorly powered.
In conclusion, given the relatively small number of patients, various dose levels, and heterogeneous tumors in this phase I study, any conclusions on the optimal scheduling of these two drugs are challenging. However, vinorelbine in combination with lapatinib, in either a continuous or intermittent schedule, is well tolerated, with encouraging results in HER2-positive advanced breast cancer. Tumor PTEN expression may potentially correlate with patient outcomes, but further work in a more homogeneous patient population is necessary. Based on the results of this trial, a phase II trial of vinorelbine and continuous lapatinib is ongoing in patients with HER2-positive metastatic breast cancer. 
